Last reviewed · How we verify

Xarlin (Levocetirizine)

HK inno.N Corporation · FDA-approved active Small molecule

Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms.

Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.

At a glance

Generic nameXarlin (Levocetirizine)
Also known asCosalin (Petasites hybridus CO2 extract), Xyarin (levocetirizine)
SponsorHK inno.N Corporation
Drug classH1-receptor antagonist (second-generation antihistamine)
TargetH1 receptor
ModalitySmall molecule
Therapeutic areaAllergy/Immunology
PhaseFDA-approved

Mechanism of action

Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It crosses the blood-brain barrier minimally, reducing sedation compared to first-generation antihistamines. By competitively blocking H1 receptors, it prevents histamine-mediated allergic responses including itching, urticaria, and rhinitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: